Psychoactive drugs

Georgia Awards Medical Cannabis License to Natures GA, LLC

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Cannabis, Psychoactive drugs, Cannabis law, Drug control law, Legality of cannabis, Drug culture

DUBLIN, Ga., July 27, 2021 /PRNewswire/ --Nature's GA, LLC, which is operated by Nature's Medicines, announced today that on July 24, 2021, the Georgia Access to Medical Cannabis Commission announced its decision to award a Class 2 Low-THC Oil Production License to the company.

Key Points: 
  • DUBLIN, Ga., July 27, 2021 /PRNewswire/ --Nature's GA, LLC, which is operated by Nature's Medicines, announced today that on July 24, 2021, the Georgia Access to Medical Cannabis Commission announced its decision to award a Class 2 Low-THC Oil Production License to the company.
  • "We want to thank the Georgia Access to Medical Cannabis Commission for its hard work, particularly given the many challenges the COVID pandemic presented," stated Jigar Patel, President and CEO ofNature's Medicines.
  • "We are honored to have been awarded this license as a result of a very competitive process.
  • Nature's Medicines is headquartered in Phoenix, Arizona and believes in the restorative power of cannabis.

DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Branches of biology, Mycotoxins, Organophosphates, Psilocybin, Plants, Cannabis, Roggen

"Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.

Key Points: 
  • "Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.
  • Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization.
  • Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development.
  • Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada.

Share Your Pack, Not Your Pre-Roll: Canopy Growth Unveils New PRJ Line-Up

Retrieved on: 
Tuesday, July 27, 2021
Cannabis, Cannabis smoking, Psychoactive drugs, Canopy Growth, S&P/TSX 60, Effects of cannabis, Constellation Brands

These products showcase thecontinued evolution of Canopy Growth's pre-roll portfolio in line with consumer preference providing Canadians with smaller joints in larger pack sizes of 8 or 10.

Key Points: 
  • These products showcase thecontinued evolution of Canopy Growth's pre-roll portfolio in line with consumer preference providing Canadians with smaller joints in larger pack sizes of 8 or 10.
  • In time for summer socializing, this is the perfect way to enjoy and share cannabis in a group setting, without having to pass a single joint around.
  • Tweed Quickies and Ace Valley Pinners are available for purchase nationally via legal recreational cannabis retail locations and ecommerce channels.
  • Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Amines, Entheogens, Ayahuasca, N,N-Dimethyltryptamine, Hallucinations, Psychedelic drug

Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc.  (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines are pleased to announce the DMT Conference.

Key Points: 
  • The two-day virtual conference is to take place on September 9-10th 2021, starting at 12 pm EDT.
  • Join us as we take a scientific deep dive into the dynamic field of DMT therapeutics, with expert panels and engaging discussions.
  • Our Molecular Masterclasses are a speaker series designed for deep dives into the world's favourite psychoactive and psychedelic substances.
  • Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world.

Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Euphoriants, Medicinal plants, Cannabis, Cannabis smoking, Clever, Plants, University of California, Davis, Psychoactive drugs, Geography of California

NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced a joint partnership with the intent to study the DNA sequence variation of three Clever Leaves’ cannabis cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), through an accepted research sponsorship from BRC, will lead the extraction and analysis of DNA to elucidate genetic variants taken from various genetic lines of Cannabis sativa.

Key Points: 
  • The initiative is part of Project Change Lives; Clever Leaves $25M product pledge to aid cannabis research in the U.S.
  • UC Davis will be the first major research institution to collaborate in the investigation of Clever Leaves Colombian and Portuguese, pharmaceutical-grade cannabis as part of Project Change Lives.
  • We are honored to collaborate with the UC Davis Plant Science department, said Kyle Detwiler, CEO of Clever Leaves.
  • To eliminate an additional impediment to the advancement of scientific knowledge around cannabis, this research material will be provided at no cost to Clever Leaves research partners.

Flor Americas Partners with Biosintex Laboratorios to Supply Cannabinoids for Argentina’s Pharmaceutical Market

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Alternative medicine, Health, Pharmaceutical, Medical Supplies, Cannabis, Cannabis smoking, Entheogens, Euphoriants, Legality of cannabis, Psychoactive drugs, Medical specialties, Flor Americas, Biosintex Laboratorios, FLOR AMERICAS, BIOSINTEX LABORATORIOS

Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.

Key Points: 
  • Additionally, Flor Americas will secure Biosintex Laboratorios long-term cannabinoid supply agreements to commercialize its innovative formulations for Argentinas burgeoning medical cannabis market.
  • During the past 20 years, Biosintex Laboratorios has earned a reputation for developing and manufacturing world-class pharmaceuticals.
  • Recently, Biosintex Laboratorios received authorization to import CBD from a producer within Flor Americas network.
  • Biosintex Laboratorios is an Argentine pharmaceutical company that develops and manufactures medicinal products with more than 20 years of experience in the market.

Jane Technologies Enters Canadian Market Through Partnership with Leading Canadian Retailer, High Tide

Retrieved on: 
Tuesday, July 27, 2021
E-commerce, Electronics industry, Non-store retailing, Supply chain management, Cannabis, Marketplace, Industry economics), Economic taxonomy, Psychoactive drugs

Our partnership with High Tide is a testament to Jane's e-commerce solutions, and ability to integrate across nearly 90 storefronts without disruption."

Key Points: 
  • Our partnership with High Tide is a testament to Jane's e-commerce solutions, and ability to integrate across nearly 90 storefronts without disruption."
  • Jane is the trusted e-commerce partner for over 2,000 dispensaries and brands across 34 U.S. markets and the Canadian market.
  • Jane is the cannabis industry's first fully automated e-commerce solution, powering 2,000+ dispensaries and brands across 34 state markets and the Canadian market.
  • For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com .

BC Craft Supply Co Debuts Grizzlers Brand in Alberta Through Revolutionary $1 “Buck a Joint” S^MPLE by AHLOT™ Program.

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Psychoactive drugs, Cannabis smoking, Euphoriants, Medicinal plants, Drug culture, Cannabis culture, Cannabis, Effects of cannabis

The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.

Key Points: 
  • The S^MPLE by AHLOT program brings traditional CPG sampling to the cannabis industry, in a compliant manner.
  • BC Craft Supply Co Ltd is a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy.
  • BC Craft works with local artists cross-sector and remains fervently committed to keeping the art, technique, and purity of their pursuit.
  • For AHLOT media information:
    THE CANADIAN SECURITIES EXCHANGE (THE CSE) HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE.

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

Retrieved on: 
Tuesday, July 27, 2021
Psychoactive drugs, Entheogens, Branches of biology, NMDA receptor antagonists, Indole alkaloids, Drug rehabilitation, Ibogaine, Tabernanthe iboga, Legal status of ibogaine by country

During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.

Key Points: 
  • During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing.
  • As first announced on July 13, 2021, MINDCURE has also filed patent applications for two routes of chemical synthesis of ibogaine.
  • Ibogaine is a psychoactive substance that can be found naturally in the roots of the iboga tree, which grows in Africa.
  • "We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes," said Kelsey Ramsden, President and CEO of MINDCURE.

Curaleaf International Launches Second Medical Cannabis Flower Product for UK Market

Retrieved on: 
Tuesday, July 27, 2021
Alternative medicine, Health, Science, Pharmaceutical, Research, Medicinal plants, Psychoactive drugs, Health sciences, Herbalism, Cannabis smoking, Entheogens, Euphoriants, Branches of biology, Curaleaf, Cannabis, Medical cannabis, Effects of cannabis

Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.

Key Points: 
  • Curaleaf International (formerly EMMAC Life Sciences Group), (Curaleaf International), Europes largest vertically integrated cannabis company, is pleased to announce the launch of its second range of medical cannabis flower products for the UK market.
  • The new products are being manufactured in the UK and will be an extension to Curaleaf Internationals existing range of medical cannabis flower and oil products.
  • Antonio Costanzo, CEO of Curaleaf International, commented: We are very pleased to extend our range of medical cannabis products for the UK market.
  • As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.